Sunday's inaugural 12-team College Football Playoff bracket reveal officially set the stage for the most anticipated postseason the sport has ever seen. Eight more spots in the playoff field have created two extra rounds to determine a national champion, which could come from the Big Ten, the Southeastern Conference or even the Mountain West! Now that the initial matchups are set, it's time to examine the FanDuel odds for the first-round games and, of course, the latest national championship odds. CFP Bracket: Odds for First-Round Games Oregon's win over Penn State in the Big Ten championship locked the Ducks into the No. 1 seed, while Georgia's overtime triumph over Texas for the SEC crown moved the Bulldogs up to No. 2. Boise State slotted in at No. 9 in the final CFP rankings but is the No. 3 seed thanks to its win over UNLV in the Mountain West championship. With SMU losing to Clemson in the Atlantic Coast Conference title game, No. 12-ranked Arizona State is the four seed after it throttled Iowa State to win the Big 12. The top four teams get a bye, with the 5-12 seeds meeting in the first round. 12-seed Clemson (+330) vs. 5-seed Texas (-11.5) Texas was favored to win the SEC and lock down a top-four seed, but Clemson was not expected to beat SMU for the ACC title. The Longhorns will therefore hunt redemption, while Dabo Swinney's team is essentially playing with house money. The winner will face Arizona State in the Peach Bowl. 9-seed Tennessee (+215) vs. 8-seed Ohio State (-7.5) The third-highest-ranked team from the SEC (No. 7 Tennessee) will face off with the third-highest-ranked squad from the Big Ten (No. 6 Ohio State). This game brings the Buckeyes a chance at redemption for their embarrassing loss to Michigan to end the regular season. The winner will travel to the Rose Bowl to play Oregon. 11-seed SMU (+240) vs. 6-seed Penn State (-7.5) Concerns over strength of schedule dog both teams. Both have 11-2 records and were runners-up in their respective conferences. Penn State's only win over a ranked opponent was against then-No. 19 Illinois in Week 4, while SMU has knocked off then-No. 22 Louisville and then-No. 18 Pittsburgh. The winner will meet Boise State in the Fiesta Bowl. 10-seed Indiana (+230) vs. 7-seed Notre Dame (-7.5) The Hoosiers may be the biggest surprise in college football this season, although their inclusion came with a few concerns over the strength of their schedule. After falling flat in a potential statement game against then-No. 2 Ohio State on Nov. 23, Indiana can prove its might against a Fighting Irish squad that won its last 10 games. The winner will take on Georgia in the Sugar Bowl. National Championship Odds and Picks Oregon was the betting favorite (odds via FanDuel) prior to the final rankings reveal at +230. Post-reveal, Texas and Georgia are co-favorites at +360, followed by Oregon at +380, Ohio State at +500 and Penn State at +600. Boise State is the biggest long shot at +7500 despite having a first-round bye. Like Boise State, Arizona State saw its odds go from +3500 to +6000 even though it doesn't play until the quarterfinals. The Picks are In... First-Round Best Bet: Indiana-Notre Dame UNDER 51.5-both teams have solid offenses but will find it difficult to move the ball against the other's defense. Upset Special: Clemson (+340) over Texas-Cade Klubnik will have his hands full against the Texas secondary, but the Clemson defense could be up for the challenge against Quinn Ewers and the Longhorns offense. National Championship Winner: Favorite-Oregon +380; Dark Horse-Notre Dame +1200; Long Shot-Arizona State +6000 --Field Level Media
‘America’s Got Talent’ judge Heidi Klum tells Fox News Digital it’s ‘no big deal’ that she went topless during her vacation. Demi Moore Demi Moore stunned in a bedazzled sheer silver gown at a Dolce & Gabbana event. (Robino Salvatore/GC Images) Demi Moore stunned when she walked the red carpet to the opening of the From the Heart to the Hands: Dolce & Gabbana exhibition party in April. She wore a bedazzled sheer silver gown, which showcased her black bra and underwear underneath. The actress paired the look with black high heels, keeping her accessories and makeup to a minimum, and wore her signature long black hair straight down. "Forever gorgeous!! Stunning!" one fan wrote in the comments section under a post she shared from the night. "I am loving seeing you back in the spot light where you deserve to be!!" another fan wrote. DEMI MOORE CONFRONTS HER OWN DEMONS IN NEW HORROR MOVIE AMID HOLLYWOOD COMEBACK Heidi Klum Heidi Klum channeled her inner Oscar when she walked the red carpet at the Vanity Fair Oscars Party in a metallic gold dress. (Jon Kopaloff/Getty Images for Vanity Fair) Heidi Klum looked like a walking Oscar statue when she walked the red carpet at the Vanity Fair Oscar Party in March, wearing a metallic gold dress with multiple cutouts on the torso and thigh-high slits on both sides. The dress, which showcased her toned abs, was paired with matching gold high heels and a gold purse. She accessorized with multiple gold rings and gold earrings with star designs hanging down. The supermodel wore her hair in a wet slicked-back look and kept her makeup natural with a nude lip. Zendaya Zendaya wore a gown inspired by Cher to the Rock & Roll Hall of Fame induction ceremony in October. (Kevin Mazur/Getty Images for the Rock and Roll Hall of Fame) Zendaya brought back the glamour of the early 1970s when she walked the red carpet at the Rock & Roll Hall of Fame induction ceremony in October in a body-baring bedazzled gold gown. The gown featured a halter neckline, which opened up into a completely open bodice, showcasing her toned abs. The skirt, which had a thigh-high slit, and the top were connected via pieces of fabric which criss-crossed over her torso. The actress and singer paired the look with pointed gold heels and layered bracelets, keeping her makeup look natural, and chose to wear her dark hair long down her back. Cher first wore a similar dress in 1972. (Michael Ochs Archives/Getty Images) ZENDAYA ON BECOMING THE YOUNGEST ACTRESS TO WIN AN EMMY FOR LEADING A DRAMA SERIES: 'I STILL CAN'T BELIEVE IT' The "Euphoria" star wore the look as an homage to legendary pop singer Cher, who was inducted into the Hall of Fame during the ceremony and who wore a similar look in the 1970s. Zendaya was the one to present Cher with the honor on stage during the event. "Thank you, Cher," Zendaya said on stage, according to a video shared by the Rock & Roll Hall of Fame. "Thank you for being an advocate, for being an ally, for paving the way for so many humans of all kinds to live in and speak their truth and to have the courage to be as daring and as open-hearted as you." Katy Perry Kary Perry left little to the imagination when she wore a faux fur coat with nothing underneath. (Stephane Cardinale - Corbis/Corbis via Getty Images) Katy Perry left little to the imagination when she arrived at the Balenciaga Fashion Show during Paris Fashion Week in June, wearing a black faux fur coat with nothing underneath, showing off her toned abs and major cleavage. The singer-songwriter paired the look with semi-sheer torn black stockings, worn over her high-heeled shoes, and black sunglasses. Her hair was pulled back in a tight braid. Zoë Kravitz Zoë Kravitz wore a completely sheer black gown to the Saint Laurent fashion show during Paris Fashion Week. (Marc Piasecki/WireImage) Zoë Kravitz showed off her slim figure when she arrived at the Saint Laurent fashion show during Paris Fashion Week in September, wearing a completely sheer black dress with floral embroidery. The dress was paired with black underwear, which was visible under the dress, black slingback heels, multiple rings and pearl earrings. The actress opted for a less dramatic makeup look, going with a nude lip, and chose to wear her hair in a slicked-back low bun. She shared photos of her in the dress on her Instagram, and fans took to the comments section to share how much they loved the look, writing "You are stunning!" and "Beauty at its peak." ZOE KRAVITZ RECALLS FEELING ‘UNCOMFORTABLE' WHILE ON LOCATION FOR 'BIG LITTLE LIES': 'WEIRD RACIST PEOPLE' Florence Pugh Florence Pugh wore a sheer black dress to the premiere of "We Live in Time." (Bryan Bedder/Variety via Getty Images) Florence Pugh wore a sheer ruffled black gown, exposing her black bra and underwear, paired with a black belt which cinched the gown in at her waist, to the September premiere of "We Live in Time." She paired the dress with black high heels, a few rings and bracelets and a necklace, wearing her short blonde hair in a half-up, half-down style. In an interview with Jodie Turner-Smith for Elle U.K. in October 2023, the actress explained she's "always been interested in wearing loud clothing" and has only gotten more confident in her personal style over the years. "I've always wanted to be bold and make a bit of a scene — I don't think that's gone away," she said. "I've become more confident in the last few years, and I think that's hugely linked to the clothes I've been wearing. The more you can enjoy it, the more [people] can see that you're enjoying it." Rita Ora Rita Ora wore a barely-there dress with beading on the red carpet at the Met Gala. (Taylor Hill/Getty Images) Rita Ora wore a custom Marni dress adorned with beads of various colors while walking the red carpet at the Met Gala in May. The beaded gown draped down the front and back of Ora's body, and included high slits on either side, going up to her shoulders, leaving much of her body exposed. To complete the look, the singer and actress wore multiple rings featuring various gemstones, including emeralds, rubies, sapphires and diamonds, as well as nude high heels and a gold purse. She wore her short hair in a wet and wavy look, and chose dramatic makeup. RITA ORA SHOWS OFF ABS IN BIKINI WHILE CELEBRATING HOLIDAYS ABOARD YACHT Kim Kardashian Kim Kardashian wore a black dress with scale-like cutouts at the Maison Margiela Haute Couture show in January. (Pierre Suu/Getty Images) Kim Kardashian wore a black gown with scale-like cutouts throughout, giving peeks at her torso and legs, while at the Maison Margiela Haute Couture show during Paris Fashion Week in January. The reality star paired the look with minimal jewelry, opting for only a large statement necklace which took up the entirety of her neck. To make sure her necklace was the focal point of her ensemble, Kardashian kept her makeup look natural and wore her hair down. She posted photos of her outfit on Instagram at the time, with fans quickly taking to the comments section to fan her with compliments, writing, "They can never make me hate you Kimberly," and "Beyond stunning." LIKE WHAT YOU’RE READING? CLICK HERE FOR MORE ENTERTAINMENT NEWS Kelsea Ballerini Kelsea Ballerini wore a sheer dress with floral designs on the Met Gala red carpet. (John Shearer/WireImage) Kelsea Ballerini wore a sheer Michael Kors gown with pink, orange and yellow flowers embroidered on it throughout, leaving her stomach and legs exposed, when she walked the red carpet at the Met Gala in May. The "I Hate Love Songs" singer paired the gown with nude heels, floral-shaped earrings and rings adorned with diamonds and sapphires, choosing to wear her hair in a low bun with some pieces left out to frame her face. She posted photos of herself in the dress on Instagram at the time, with fans writing, "YOU NAILED IT. That’s it. Thank you," "Absolutely love the look!! You are so very beautiful!!!" and "Omg Girl, SLAY." CLICK HERE TO SIGN UP FOR THE ENTERTAINMENT NEWSLETTER Leni Klum Leni Klum wore a sheer black dress with black floral embellishments on it in May at Cannes. (Gisela Schober/Getty Images) Leni Klum attended the amfAR Chopard event at the Cannes Film Festival in May wearing a black knit dress with matching arm pieces, which also featured 3D floral details on the chest and the waist. The model paired the look with black high-heeled shoes and a diamond choker. She styled her brown hair in a half-up, half-down look, and with bold makeup featuring winged eyeliner and a dark red lip. CLICK HERE TO GET THE FOX NEWS APP Lori Bashian is an entertainment production assistant for Fox News Digital.Welcome to the latest edition of Loyalty & Rewards SA. As I write this, I can’t help but reflect on how much loyalty programmes have transformed over the years. If you’re like me, you’ve probably noticed that your inbox is packed with offers from various rewards programmes – each one trying to grab your attention with something just a little more personalised, a little more tailored to your needs. Loyalty today is about so much more than collecting points or redeeming vouchers. It’s evolved into something deeper where brands are working hard to make us feel valued, heard and truly understood. What’s fascinating is how technology is playing a central role in this shift. Brands are using advanced data analytics and artificial intelligence to craft rewards that make sense for our individual lifestyles. It’s no longer a one-size-fits-all approach but rather a thoughtful, personalised experience that keeps us engaged. In this issue, we explore some of the most exciting trends shaping the future of loyalty. Here’s to discovering the future of loyalty, one reward at a time. Brendon Petersen, EditorColorado quarterback Shedeur Sanders took quite the hit during Saturday's game against Kansas. The senior quarterback was on the receiving end of a hit to the knees by Jayhawks linebacker Dean Miller that sent Sanders to fall backwards and grip his knee. Sanders did not depart from the game, but the severity of the hit had many take to social media to criticize the hit not being penalized. This article will be updated soon to provide more information and analysis. For more from Bleacher Report on this topic and from around the sports world, check out our B/R app , homepage and social feeds—including Twitter , Instagram , Facebook and TikTok .
NEW YORK--(BUSINESS WIRE)--Dec 28, 2024-- Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Zuora, Inc. (NYSE: ZUO) to Silver Lake and an affiliate of GIC Pte. Ltd. for $10.00 per share in cash is fair to Zuora shareholders. Halper Sadeh encourages Zuora shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com . The investigation concerns whether Zuora and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Zuora shareholders; (2) determine whether Silver Lake and GIC are underpaying for Zuora; and (3) disclose all material information necessary for Zuora shareholders to adequately assess and value the merger consideration. On behalf of Zuora shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome. View source version on businesswire.com : https://www.businesswire.com/news/home/20241228245657/en/ CONTACT: Halper Sadeh LLC One World Trade Center 85th Floor New York, NY 10007 Daniel Sadeh, Esq. Zachary Halper, Esq. (212) 763-0060 sadeh@halpersadeh.com zhalper@halpersadeh.com https://www.halpersadeh.com KEYWORD: NEW YORK UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: CLASS ACTION LAWSUIT PROFESSIONAL SERVICES LEGAL SOURCE: Halper Sadeh LLC Copyright Business Wire 2024. PUB: 12/28/2024 03:40 PM/DISC: 12/28/2024 03:39 PM http://www.businesswire.com/news/home/20241228245657/en
Media Release COPENHAGEN, Denmark; December 8, 2024 Preliminary analyses from the EPCORE ® CLL-1 trial demonstrates overall response rate (ORR) of 61 percent and complete response (CR) rate of 39 percent in heavily pretreated patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) who received epcoritamab monotherapy In the study, 75 percent of evaluable responders achieved undetectable minimal residual disease (MRD), indicating no detectable disease following treatment with epcoritamab The data were selected as part of the 2024 American Society of Hematology’s (ASH’s) Annual Meeting Press Program in the Diagnosing and Treating Blood Cancers and “Almost Cancers” briefing Genmab A/S (Nasdaq: GMAB ) today announced results from the Phase 1b/2 EPCORE ® CLL-1 clinical trial evaluating epcoritamab (Abstract #883), a T-cell engaging bispecific antibody administered subcutaneously, demonstrated an overall response rate (ORR) of 61 percent and a complete response (CR) rate of 39 percent in difficult-to-treat adult patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) treated with epcoritamab monotherapy. These results, from the monotherapy expansion (EXP) cohort (n=23) of the trial, along with the first safety data from the optimization (OPT) cohort, were presented at the 66 th Annual Meeting and Exposition of the American Society of Hematology (ASH), during the ASH Annual Meeting Press Program. The data will be presented during an oral session on December 9, 2024. In the EXP cohort, the median time to response was two (2.0) months and the median time to CR was 5.6 months. Among all patients in the cohort, median progression-free survival (PFS) was 12.8 months and median overall survival (OS) was not reached (median follow-up was 22.8 months). An estimated 65 percent of patients were alive at 15 months. Among 12 responders evaluable for minimal residual disease (MRD) by next-generation sequencing in peripheral blood, nine patients (75 percent) had undetectable MRD. The most frequent non-hematologic treatment-emergent adverse events (TEAEs) in the EXP cohort were cytokine release syndrome (CRS; 96 percent), diarrhea (48 percent), peripheral edema (48 percent), fatigue (43 percent), and injection-site reaction (43 percent). Cytopenias were common (anemia, 65 percent; thrombocytopenia, 65 percent; neutropenia, 48 percent); however, most patients had baseline anemia and thrombocytopenia, suggesting that these events were largely disease-related. Three cases of immune effector cell-associated neurotoxicity syndrome (ICANS) were reported (one Grade 1; two Grade 2), and there was one clinical tumor lysis syndrome (CTLS) case (Grade 2). These cases did not lead to treatment discontinuation. Four fatal TEAEs occurred - two cases of pneumonia, one case of sepsis and one case of squamous cell carcinoma of the skin. The EXP cohort followed a 2-step step-up dose regimen, and CRS was manageable and primarily low grade (9 percent Grade 1, 70 percent Grade 2, 17 percent Grade 3). In the first data from the separate OPT cohort, which followed a 3-step step-up dose regimen, CRS severity was substantially reduced with only low-grade events (71 percent Grade 1, 12 percent Grade 2). In both cohorts, CRS events primarily occurred following the first full dose, and none led to treatment discontinuation. No ICANS or CTLS cases were reported in the OPT cohort. “These EPCORE CLL-1 data are encouraging, especially as the majority of patients were heavily pre-treated with at least four lines of therapy,” said Alexey Danilov, MD, PhD, Marianne and Gerhard Pinkus, Professor and Director of Early Clinical Therapeutics and Associate Director of the Toni Stephenson Lymphoma Center, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope. “Despite progress in treating chronic lymphocytic leukemia, there remains a tremendous need for additional therapeutic options for high-risk patients whose disease has progressed following standard chemoimmunotherapy and targeted therapies.” Additional data from the EXP cohort showed high response rates in patients with high-risk factors treated with epcoritamab, including TP53 aberrations, IGHV-unmutated disease and double-exposed disease – prognostic markers that are associated with disease progression and decreased survival. i , ii , iii In patients with TP53 aberrations (n=15), the ORR was 67 percent with a CR of 33 percent. Among patients with IGHV-unmutated disease (n=16), the ORR was 63 percent, and the CR was 44 percent. In double-refractory patients, the ORR was 53 percent, and the CR was 37 percent. All patients in the trial had prior chemoimmunotherapy, and most patients had previously received targeted therapies such as BTK and BCL2 inhibitors (double-exposed) and had high-risk disease characteristics. “Chronic lymphocytic leukemia is incurable, and patients often need a variety of treatments throughout their lifetime, especially if their disease has high-risk prognostic factors, has relapsed or has become refractory to the current standard-of-care, including targeted therapies,” said Dr. Judith Klimovsky, Executive Vice President & Chief Development Officer, Genmab. “These early data show the potential therapeutic applicability of epcoritamab in relapsed or refractory chronic lymphocytic leukemia, and further reinforce the potential of epcoritamab as a core therapy for the treatment of B-cell malignancies.” Use of epcoritamab in CLL is not approved in the U.S. or in the EU or in any other territory. The safety and efficacy of epcoritamab for use in CLL have not been established. About Chronic Lymphocytic Leukemia (CLL) Chronic lymphocytic leukemia (CLL) is the most prevalent type of leukemia, affecting over 200,000 people in the United States alone. iv Chronic lymphocytic leukemia can be classified as either slow growing (indolent) or fast growing (aggressive). v CLL is incurable, and many patients will likely relapse and progress on frontline therapies. vi Most patients will experience consecutive episodes of disease progression and will require several lines of treatment in their lifetime. vii , viii About the EPCORE ® CLL-1 Trial EPCORE ® CLL-1 is a Phase 1b/2, open-label, multi-center trial to evaluate the safety and preliminary efficacy of epcoritamab as a monotherapy and in combination with standard of care agents in patients with difficult-to-treat relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), R/R small lymphocytic lymphoma (SLL) and Richter's Syndrome (RS). The trial consists of two parts: a dose-escalation phase (Phase 1b) and an expansion phase (Phase 2). Patients with RS are only included in the expansion phase. The primary objective of Phase 1b is to determine the recommended Phase 2 dose and the maximum tolerated dose as well as establish the safety profile of epcoritamab monotherapy and epcoritamab plus venetoclax in participants with R/R CLL. The purpose of Phase 2 is to assess and evaluate the preliminary efficacy, safety and tolerability profiles of epcoritamab monotherapy and epcoritamab plus venetoclax for patients with R/R CLL and SLL. Additionally, epcoritamab monotherapy and combination therapy will be evaluated in patients with RS to assess their efficacy, safety and tolerability profiles. More information on this trial can be found at https://www.clinicaltrials.gov/ (NCT: 04623541). About Epcoritamab Epcoritamab is an IgG1-bispecific antibody created using Genmab's proprietary DuoBody ® technology and administered subcutaneously. Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response toward target cell types. Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B cells and induces T-cell-mediated killing of CD20+ cells. ix Epcoritamab (approved under the brand name EPKINLY ® in the U.S. and Japan, and TEPKINLY ® in the EU) has received regulatory approval in certain lymphoma indications in several territories. Epcoritamab is being co-developed by Genmab and AbbVie as part of the companies' oncology collaboration. The companies will share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization. Both companies will pursue additional international regulatory approvals for the investigational R/R FL indication and additional approvals for the R/R DLBCL indication. Genmab and AbbVie continue to evaluate the use of epcoritamab as a monotherapy, and in combination, across lines of therapy in a range of hematologic malignancies. This includes five ongoing Phase 3, open-label, randomized trials including a trial evaluating epcoritamab as a monotherapy in patients with R/R DLBCL compared to investigator’s choice chemotherapy ( NCT04628494 ), a trial evaluating epcoritamab in combination with R-CHOP in adult patients with newly diagnosed DLBCL ( NCT05578976 ), a trial evaluating epcoritamab in combination with rituximab and lenalidomide (R 2 ) in patients with R/R FL ( NCT05409066 ), a trial evaluating epcoritamab in combination with rituximab and lenalidomide (R 2 ) compared to chemoimmunotherapy in patients with previously untreated FL ( NCT06191744 ), and a trial evaluating epcoritamab in combination with lenalidomide compared to chemotherapy infusion in patients with R/R DLBCL ( NCT06508658 ). The safety and efficacy of epcoritamab has not been established for these investigational uses. Please visit www.clinicaltrials.gov for more information. About Genmab Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO ® ) antibody medicines. Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X . Contact: David Freundel, Senior Director, Global R&D & Portfolio Communications T: +1 609 430 2481; E: dafr@genmab.com Andrew Carlsen, Vice President, Head of Investor Relations T: +45 3377 9558; E: acn@genmab.com This Media Release contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov . Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. Genmab A/S and/or its subsidiaries own the following trademarks: Genmab ® ; the Y-shaped Genmab logo ® ; Genmab in combination with the Y-shaped Genmab logo ® ; HuMax ® ; DuoBody ® ; HexaBody ® ; DuoHexaBody ® , HexElect ® and KYSOTM. EPCORE ® , EPKINLY ® , TEPKINLY ® and their designs are trademarks of AbbVie Biotechnology Ltd. i Campo, et al. TP53 Aberrations in Chronic Lymphocytic Leukemia: An Overview of the Clinical Implications of Improved Diagnostics. Haematologica . 2018 Nov 15;103(12):1956–1968. https://haematologica.org/article/view/8691 .. ii Galieni, et al. Unmutated IGHV at Diagnosis in Patients With Early Stage CLL Independently Predicts for Shorter Follow-Up Time to First Treatment (TTFT). Leukemia Research. 2024. https://doi.org/10.1016/j.leukres.2024.107541 . iii Zuber, et al. Efficacy and Effectiveness Outcomes of Treatments for Double-Exposed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients: A Systematic Literature Review. Cancer Medicine . 2024. https://doi.org/10.1002/cam4.70258 iv Fedele, et al. Chronic Lymphocytic Leukemia: Time to Care for the Survivors. Journal of Clinical Oncology . 2024. https://ascopubs.org/doi/10.1200/JCO.23.02738 . v Penn Medicine. Chronic Lymphocytic Leukemia (CLL). Accessed November 2024. https://www.pennmedicine.org/cancer/types-of-cancer/leukemia/types-of-leukemia/chronic-lymphocytic-leukemia . vi Odetola, et al. Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). Curr Hematol Malig Rep . 2023 Jun 6:1–14. doi: 10.1007/s11899-023-00700-z vii Moreno, Carol. Standard Treatment Approaches for Relapsed/Refractory Chronic Lymphocytic Leukemia After Frontline Chemoimmunotherapy. Hematology Am Soc Hematol Educ Program . 2020 Dec 4;2020(1):33-40. doi: 10.1182/hematology.2020000086. viii Leukemia & Lymphoma Society. Relapsed and Refractory CLL. Accessed November 2024. https://www.lls.org/leukemia/chronic-lymphocytic-leukemia/treatment/relapsed-and-refractory . ix Engelberts PJ, et al. DuoBody-CD3xCD20 Induces Potent T-Cell-Mediated Killing of Malignant B Cells in Preclinical Models and Provides Opportunities for Subcutaneous Dosing. EBioMedicine . 2020;52:102625. doi: 10.1016/j.ebiom.2019.102625. Media Release no. i19 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122 Genmab A/S Carl Jacobsens Vej 30 2500 Valby Denmark Attachment 081224_MRi19_Epcor CLL ASH Data GLOBALRexas Finance (RXS) emerges as a promising investment opportunity, challenging Dogecoin’s dominance in the cryptocurrency market. Offering a starting price of $0.15 and a robust tokenomics structure, RXS positions itself as a potential 10x profit driver. Meanwhile, Dogecoin faces technical resistance, signalling a mixed outlook for short-term gains. Rexas Finance: Revolutionizing Real-World Asset Tokenization Rexas Finance integrates real-world assets (RWA) with blockchain technology, redefining traditional financial markets. By enabling fractional ownership of RWA, the platform opens pathways for investors while addressing illiquidity and high costs. With $379 trillion worth of global assets ripe for tokenization, Rexas Finance offers immense scalability. The platform’s QuickMint Bot and GenAI systems simplify asset tokenization, making blockchain accessibility seamless for businesses and individuals. The RXS token’s distribution strategy also fosters ecosystem growth, with 42.5% allocated for presale to promote early adoption. Its circulating supply of 1 billion tokens ensures sustainable demand as more users engage with the ecosystem. The combination of advanced technology and strategic distribution sets RXS apart as an investment option. Analysts compare RXS’s growth trajectory to Ethereum, hinting at substantial long-term profitability for early investors. At its current price of $0.15, RXS offers a cost-effective entry into the burgeoning RWA market. Dogecoin: Fluctuations Amid Mixed Market Signals Dogecoin's recent price action highlights its volatility, with notable declines followed by a partial recovery in recent days. After dropping to $0.2663, buyers leveraged the low price as an entry point, pushing it to $0.34. Market momentum suggests potential for a rally, but key resistance levels remain a challenge. Technical analysis shows Dogecoin trading near the Gaussian Channel mid-band, a critical support zone. If momentum sustains, the channel’s upper boundary could signal the start of another rally. However, Dogecoin’s reliance on market sentiment and speculative interest makes its trajectory unpredictable. Despite its meme coin status, Dogecoin still attracts attention due to its established market presence. However, compared to RXS, its utility and growth potential seem limited in a rapidly evolving blockchain space. RXS vs. DOGE: Why Rexas Finance May Be the Better Bet Rexas Finance provides a clear use case by tokenizing real-world assets and addressing tangible market problems like illiquidity and high costs. In contrast, Dogecoin’s value largely depends on speculative trading and social media hype. RXS's robust ecosystem and strategic vision present a more stable and scalable investment opportunity. Investors seeking a 10x return may find RXS’s $0.15 price highly attractive, given its alignment with emerging blockchain trends. As institutional adoption of tokenized assets grows, RXS’s value could skyrocket, mirroring Ethereum’s historic rise. Conclusion Rexas Finance is a transformative force in blockchain, bridging real-world assets with decentralized finance. Its low entry price, strong tokenomics, and innovative tools position it as a better investment than Dogecoin. For investors eyeing a quick 10x profit, RXS represents a compelling opportunity in the evolving crypto landscape. Website: https://rexas.com Whitepaper: https://rexas.com/rexas-whitepaper.pdf Twitter/X: https://x.com/rexasfinance Telegram: https://t.me/rexasfinance Join our WhatsApp Channel to get the latest news, exclusives and videos on WhatsApp _____________ Disclaimer: Analytics Insight does not provide financial advice or guidance. Also note that the cryptocurrencies mentioned/listed on the website could potentially be scams, i.e. designed to induce you to invest financial resources that may be lost forever and not be recoverable once investments are made. You are responsible for conducting your own research (DYOR) before making any investments. Read more here.Applicants sue Minnesota’s Office of Cannabis Management over disqualification
Strictly Come Dancing returned to screens with week 10 of the star-studded competition following the highly anticipated Blackpool instalment . Ahead of the episode, head judge Shirley Ballas took to social media to flaunt her glamorous outfit with a stunning photo. The 64-year-old looked incredible in an all-black outfit which featured a sculptural detail on the strapless fitted jumpsuit. Shirley was also all smiles in the post captioned: “Ready for Week 10 ... Tonight is the Sambathon so we’re all very excited for that. Good luck to all the couples.” However, among the praise from adorning fans, one viewer pointed out a glaring error with her entrance into the competition. Next week, I promise x https://t.co/prvjn8LjjJ Taking to the comments, @Tobleroni45 slammed the judge and remarked: “Try and take your seat on time for once! #timing.” After the show, Shirley responded: “Next week, I promise x.” However, many of her fans came into her defence including @greg_j_davis who shared: “Please ignore them - the judges make strictly what it is! :).” @Thismightchange added: “They will be telling you that you breathe too much soon.” At the start of the episode, Shirley was among the other judges Anton Du Beke , Motsi Mabuse and Craig Revel Horwood as they appeared from behind the iconic staircase. After being introduced, the panellist performed a short and fun routine to MC Hammer’s 1990 hit Can’t Touch This. They then danced to their seats and closed their routine with a dramatic pose.
Drones for commercial and recreational use have grown rapidly in popularity, despite restrictions on who can operate them and where they can be flown. No-fly zones are enforced around airports, military installations, nuclear plants, certain landmarks including the Statue of Liberty, and sports stadiums during games. Not everybody follows the rules. Sightings at airports have shut down flights in a few instances. Reported sightings of what appear to be drones flying over New Jersey at night in recent weeks have created anxiety among some residents, in part because it is not clear who is operating them or why. Some state and local officials have called for stricter rules to govern drones. After receiving reports of drone activity last month near Morris County, New Jersey, the Federal Aviation Administration issued temporary bans on drone flights over a golf course in Bedminster , New Jersey, that is owned by President-elect Donald Trump, and over Picatinny Arsenal Military Base . The FAA says the bans are in response to requests from “federal security partners.” The FAA is responsible for the regulations governing their use , and Congress has written some requirements into law. With a 2018 law, the Preventing Emerging Threats Act, Congress gave certain agencies in the Homeland Security and Justice departments authority to counter threats from unmanned aircraft to protect the safety of certain facilities. New drones must be outfitted with equipment allowing law enforcement to identify the operator, and Congress gave the agencies the power to detect and take down unmanned aircraft that they consider dangerous. The law spells out where the counter-drone measures can be used, including “national special security events” such as presidential inaugurations and other large gatherings of people. To get a “remote pilot certificate,” you must be at least 16 years old, be proficient in English, pass an aeronautics exam, and not suffer from a ”mental condition that would interfere with the safe operation of a small unmanned aircraft system.” Yes, but the FAA imposes restrictions on nighttime operations. Most drones are not allowed to fly at night unless they are equipped with anti-collision lights that are visible for at least 3 miles (4.8 kilometers). Over the past decade, pilots have reported hundreds of close calls between drones and airplanes including airline jets. In some cases, airplane pilots have had to take evasive action to avoid collisions. Drones buzzing over a runway caused flights to be stopped at London’s Gatwick Airport during the Christmas travel rush in 2018 and again in May 2023 . Police dismissed the idea of shooting down the drones, fearing that stray bullets could kill someone. Advances in drone technology have made it harder for law enforcement to find rogue drone operators — bigger drones in particular have more range and power. Some state and local officials in New Jersey are calling for stronger restrictions because of the recent sightings, and that has the drone industry worried. Scott Shtofman, director of government affairs at the Association for Uncrewed Vehicle Systems International, said putting more limits on drones could have a “chilling effect” on “a growing economic engine for the United States.” “We would definitely oppose anything that is blindly pushing for new regulation of what are right now legal drone operations,” he said. AirSight, a company that sells software against “drone threats,” says more than 20 states have enacted laws against privacy invasion by drones, including Peeping Toms. Will Austin, president of Warren County Community College in New Jersey, and founder of its drone program, says it's up to users to reduce public concern about the machines. He said operators must explain why they are flying when confronted by people worried about privacy or safety. “It's a brand new technology that's not really understood real well, so it will raise fear and anxiety in a lot of people,” Austin said. “We want to be good professional aviators and alleviate that.” Associated Press reporter Rebecca Santana in Washington, D.C., contributed.
British-Canadian computer scientist Geoffrey Hinton and co-laureate John Hopfield are set to receive the Nobel Prize for physics on Tuesday in Stockholm. Read this article for free: Already have an account? To continue reading, please subscribe: * British-Canadian computer scientist Geoffrey Hinton and co-laureate John Hopfield are set to receive the Nobel Prize for physics on Tuesday in Stockholm. Read unlimited articles for free today: Already have an account? British-Canadian computer scientist Geoffrey Hinton and co-laureate John Hopfield are set to receive the Nobel Prize for physics on Tuesday in Stockholm. The pair landed the accolade because they used physics to develop artificial neural networks, which help computers learn without having to program them. These networks form the foundation of machine learning, a computer science that relies on data and algorithms to help artificial intelligence mimic the human brain. Hinton and Hopfield’s path to the Nobel began when Hopfield, who is now a professor emeritus at Princeton University, invented a network in 1982 that could store and reconstruct images in data. The Hopfield network uses associate memory, which humans use to remember what something looks like when it’s not in front of them or to conjure up a word they know but seldom use. The network can mirror this process because it stores patterns and has a method for recreating them. When the network is given an incomplete or slightly distorted pattern, the method then searches for the stored pattern that is most similar to recreate data. This means if a computer was shown, for example, a photo of dog where only part of the animal was visible, it could use the network to piece together the missing part of the image and recognize it was depicting a dog. Hinton, who was working at Carnegie Mellon University in Pittsburgh in 1985, used the Hopfield network as the foundation for a new network he called the Boltzmann machine. Its name came from the nineteenth-century physicist Ludwig Boltzmann. The Boltzmann machine learns from examples, rather than instructions, and when trained, can recognize familiar characteristics in information, even if it has not seen that data before. Winnipeg Jets Game Days On Winnipeg Jets game days, hockey writers Mike McIntyre and Ken Wiebe send news, notes and quotes from the morning skate, as well as injury updates and lineup decisions. Arrives a few hours prior to puck drop. The Royal Swedish Academy of Sciences, which gives out the Nobel, likens this to how humans may be able to identify someone as a relative of one of their friends, even if they’ve never met this person before, because of they share similar traits. The Boltzmann machine works in a similar way, classifying images or creating new examples based on the patterns it was trained on. This kind of technology can help suggest films or television shows based on a user’s preferences and past viewing history The Hopfield network and Boltzmann machine are considered to have laid the groundwork for modern AI. Hinton, a professor emeritus at the University of Toronto, went on to win the A.M. Turing Award, known as the Nobel Prize of computing, with fellow Canadian Yoshua Bengio and American Yan LeCun in 2018. He is often called the godfather of AI. This report by The Canadian Press was first published Dec. 8, 2024. Advertisement AdvertisementPutin apologizes for crash but stops short of saying Azerbaijani plane was shot down
Dallas (5-8) at Carolina (3-10) Sunday, 1 p.m. EST, FOX. BetMGM Odds: Panthers by 3. Against the spread: Cowboys 4-9, Panthers 6-7. Series record: Cowboys lead 11-3. Last meeting: Cowboys beat Panthers 33-10 on Nov. 19, 2023 in Carolina. Last week: Cowboys lost to Bengals 27-20; Panthers lost to Eagles 22-16. Cowboys offense: overall (20), rush (28), pass (11), scoring (21) Cowboys defense: overall (25), rush (30), pass (22), scoring (31) Panthers offense: overall (30), rush (22), pass (27), scoring (28) Panthers defense: overall (31), rush (32), pass (12), scoring (32) Turnover differential: Cowboys minus-8; Panthers minus-5. Panthers edge rusher Micah Parsons vs. Panthers offensive line. Parsons seems to be getting better as the season progresses and will be a tough matchup for Carolina's offensive line regardless of where he lines up. Parsons has 3 1/2 sacks over his past three games. WR Adam Thielen. The veteran wide receiver was Bryce Young's favorite option last season and is finally developing into that again this season after battling back from a hamstring injury that left him on injured reserve. Thielen has 17 catches on 21 targets for 201 yards and a touchdown over the past two games. When the Panthers need a first down on fourth down, the pass is almost always going to Thielen. Cowboys RB Rico Dowdle vs. NFL's worst run defense. Dowdle has had the first two 100-yard outings of his career the past two weeks, resetting his career best both times. The undrafted fifth-year player on an expiring contract had 131 yards in the loss to the Bengals. Since taking over as the lead back at the start of November, Dowdle is averaging 16 carries and 81 yards with a touchdown rushing and another receiving. On Sunday, he will face the league’s 32nd-ranked run defense. Carolina allowed Philadelphia’s Saquon Barkley to run for 124 yards last week and Tampa Bay’s Bucky Irving to run for a career-high 152 yards the week before that. The Panthers are allowing more than 170 yards per game on the ground and 4.97 yards per carry. Cowboys LB DeMarvion Overshown was set for season-ending surgery on the right knee he injured in the fourth quarter of the loss to the Bengals. The second-year player from Texas missed all of his rookie season after tearing a ligament in his left knee in a preseason game. ... DE DeMarcus Lawrence, who hasn’t played since Week 4, is close to returning from a foot injury. With the playoff hopes all but gone, the question remains whether to press the 32-year-old into action. Lawrence is on an expiring contract. ... Rookie C Cooper Beebe sustained a concussion against Cincinnati.. ... The Panthers are hoping to get WR Jalen Coker back on the field this week after he has missed the past three games with a quad injury. ... Also, No. 1 CB Jaycee Horn has been playing with a groin injury, and that could be problematic against CeeDee Lamb. The Cowboys are 7-2 against the Panthers since losing a wild-card game at Carolina 29-10 during the 2003 season, the first of Pro Football Hall of Fame coach Bill Parcells’ four years leading Dallas. The Cowboys are 4-2 on the road this season, including victories over playoff contenders Pittsburgh and Washington. ... QB Cooper Rush is 2-3 filling in for Dak Prescott, who is out for the season after surgery for a torn hamstring. Assuming Rush starts, this will be his longest stint as Prescott’s replacement. He went 4-1 in 2022 after Prescott broke the thumb on his throwing hand in the opener. ... Dowdle’s 7.3-yard average per carry on 18 attempts against the Bengals was the highest for a Dallas back since Ezekiel Elliott averaged 7.9 per carry at Philadelphia in 2018. ... WR CeeDee Lamb has just one 100-yard receiving game this season after finishing with eight in his breakout 2023 All-Pro season. But Lamb has five other games with at least 89 yards. He has reached 1,000 scrimmage yards in each of his first five seasons, the fifth receiver to do that. ... S Malik Hooker’s interception of Joe Burrow was his second of the season. He has seven interceptions in his four Dallas seasons. He also had seven in four years with Indianapolis, where he spent four injury-filled years as a 2017 first-round draft pick. ... The Panthers have endured six straight seasons with at least 10 losses. ... Carolina’s past five games have come down to the last possession. ... Panthers 1,000-yard RB Chuba Hubbard needs one rushing touchdown to pass Stephen Davis for fifth in team history. He is also 9 rushing yards away from reaching 3,000 for his career. ... Rookie WR Xavier Legette had three drops last week vs. the Eagles, including one for a potential go-ahead score in the final minute. ... OLB Jadeveon Clowney is tied for 11th in sacks among active NFL players. ... The Panthers have 15 sacks in the past four games. Carolina’s improved pass rush has coincided with OLB D.J. Wonnum getting on the field after missing the first nine games of the season on injured reserve. Chuba Hubbard is expected to see the overwhelming majority of carries for the Panthers, who are now thin at the position. Miles Sanders and Jonathon Brooks are on injured reserve and Raheem Blackshear is working through a chest injury. That leaves Mike Boone as the Hubbard's backup. NFL: https://apnews.com/hub/nflPutin apologizes for crash but stops short of saying Azerbaijani plane was shot down
NEW YORK , Dec. 12, 2024 /PRNewswire/ -- Lument Finance Trust, Inc. (NYSE: LFT ) ("LFT" or the "Company") announced the declaration of a cash dividend of $0.08 per share of common stock with respect to the fourth quarter of 2024. The Company also announced the declaration of a one-time special cash dividend of $0.09 per share of common stock due to real estate investment trust tax considerations. These dividends are payable on January 15, 2025 , to common stockholders of record as of the close of business on December 31, 2024 . The Company also announced the declaration of a cash dividend of $0.4921875 per share of 7.875% Cumulative Redeemable Series A Preferred Stock. The dividend is payable on January 15, 2025 to preferred stockholders of record as of the close of business January 2, 2025 . Javascript is required for you to be able to read premium content. Please enable it in your browser settings.None
Flames prospect Zayne Parekh looking to keep Canadian world junior dream alive